DE60335797D1 - Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten - Google Patents

Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten

Info

Publication number
DE60335797D1
DE60335797D1 DE60335797T DE60335797T DE60335797D1 DE 60335797 D1 DE60335797 D1 DE 60335797D1 DE 60335797 T DE60335797 T DE 60335797T DE 60335797 T DE60335797 T DE 60335797T DE 60335797 D1 DE60335797 D1 DE 60335797D1
Authority
DE
Germany
Prior art keywords
insulin
formulations containing
containing monomeric
acylated
soluble formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335797T
Other languages
English (en)
Inventor
Liselotte Langkjaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE60335797D1 publication Critical patent/DE60335797D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE60335797T 2002-05-07 2003-05-02 Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten Expired - Lifetime DE60335797D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200683 2002-05-07
PCT/DK2003/000288 WO2003094956A1 (en) 2002-05-07 2003-05-02 Soluble formulations comprising monomeric insulin and acylated insulin

Publications (1)

Publication Number Publication Date
DE60335797D1 true DE60335797D1 (de) 2011-03-03

Family

ID=29414624

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335797T Expired - Lifetime DE60335797D1 (de) 2002-05-07 2003-05-02 Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten

Country Status (8)

Country Link
US (2) US20040006000A1 (de)
EP (1) EP1506230B1 (de)
JP (2) JP5599543B2 (de)
AT (1) ATE496064T1 (de)
AU (1) AU2003236201A1 (de)
DE (1) DE60335797D1 (de)
ES (1) ES2360182T3 (de)
WO (1) WO2003094956A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003236201A1 (en) * 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
BRPI0413276B8 (pt) * 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
US20090011976A1 (en) * 2004-11-12 2009-01-08 Novo Nordisk A/S Stable Formulations Of Peptides
PL1969004T3 (pl) * 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
FR2896247B1 (fr) 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
WO2008034881A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
PL2597103T3 (pl) 2007-11-16 2017-04-28 Novo Nordisk A/S Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
EP2254905B1 (de) 2008-03-14 2016-12-14 Novo Nordisk A/S Proteasestabilisierte insulinanaloga
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
ES2570937T3 (es) * 2008-08-07 2016-05-23 Biocon Ltd Un proceso para la preparación de compuestos de insulina
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
MX2011007929A (es) 2009-01-28 2011-08-17 Smartcells Inc Sistemas basados en conjugados para entrega farmacologica controlada.
JP2012516340A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 合成コンジュゲートおよびその使用
CN102369031B (zh) * 2009-02-04 2015-11-25 赛诺菲-安万特德国有限公司 用于血糖控制的医疗设备和方法
EP2408808A4 (de) 2009-03-20 2015-05-06 Smartcells Inc Terminal-funktionalisierte konjugate und ihre verwendung
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
KR101972301B1 (ko) 2009-11-13 2019-04-25 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
US8950394B2 (en) 2010-01-12 2015-02-10 Dance Biopharm Inc. Preservative-free single dose inhaler systems
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
CA2809321C (en) 2010-08-30 2018-08-14 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
RU2013130374A (ru) * 2010-12-14 2015-01-20 Ново Нордиск А/С Препарат, содержащий инсулин, никотинамид и аминокислоту
US20130331320A1 (en) 2010-12-14 2013-12-12 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HUE027989T2 (en) 2011-08-29 2016-11-28 Sanofi Aventis Deutschland A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013153000A2 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
BR112015010799B1 (pt) 2012-11-13 2023-01-17 Adocia Composição em solução aquosa, e, formulação farmacêutica
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
AU2015205620A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin aspart
AU2015205621A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP7173953B2 (ja) * 2014-01-09 2022-11-16 サノフイ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
JO3624B1 (ar) * 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
BR112017018060A2 (pt) 2015-02-25 2018-04-10 Dance Biopharm Inc formulação de insulina, dose de unidade, e, método de tratar um indivíduo com diabetes melito.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
AU2017378102B2 (en) 2016-12-16 2022-10-13 Novo Nordisk A/S Insulin containing pharmaceutical compositions
GB201707187D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3740212A4 (de) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. Konjugatbasierte systeme für kontrollierte insulinabgabe
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CA3173417A1 (en) 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
KR20230110505A (ko) 2020-11-19 2023-07-24 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 인슐린 유사체
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU550068B2 (en) 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
RU2164520C2 (ru) * 1993-09-17 2001-03-27 Ново Нордиск А/С Производное инсулина, растворимая пролонгированная фармацевтическая композиция, способ пролонгирования гипогликемического действия при лечении диабета
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
KR19980703039A (ko) 1995-03-17 1998-09-05 켈스버그 라아스 인슐린 유도체
US20010041786A1 (en) 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
PT1172114E (pt) * 1998-10-16 2005-02-28 Novo Nordisk As Preparacoes concentradas e estaveis de insulina para administracao pulmonar
WO2000043034A2 (en) * 1999-01-26 2000-07-27 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
US6589229B1 (en) * 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
US8003605B2 (en) * 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
AU2003236201A1 (en) * 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin

Also Published As

Publication number Publication date
EP1506230B1 (de) 2011-01-19
US20040006000A1 (en) 2004-01-08
US7387996B2 (en) 2008-06-17
EP1506230A1 (de) 2005-02-16
ATE496064T1 (de) 2011-02-15
AU2003236201A1 (en) 2003-11-11
US20050261168A1 (en) 2005-11-24
JP2006511441A (ja) 2006-04-06
ES2360182T3 (es) 2011-06-01
JP5599543B2 (ja) 2014-10-01
JP2012233003A (ja) 2012-11-29
WO2003094956A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
DE60335797D1 (de) Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
MXPA03011935A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
IL169469A (en) Folic acid derivatives containing disulfide bonds, their pharmaceutical compositions and their use
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
SE0301653D0 (sv) Novel compounds
PT1506185E (pt) Compostos novos e sua utilizacao
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
ZA200501714B (en) Analogues of vitamin d
ATE431749T1 (de) Topische zusammensetzung enthaltend ein cyclofructan, einen träger und einen arzneistoff
MXPA06002349A (es) Derivados de aminopropanol.
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
EP1731609A4 (de) Rad51-expressionsinhibitor, den inhibitor als wirkstoff enthaltender arzneistoff und nutzung davon
RS51575B (en) ESCITALOPRAM CRYSTAL DATABASE AND ORODISPERSIBLE TABLES CONTAINING ESCITALOPRAM DATABASE
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety
HUP0402028A3 (en) Unsaturated 1-amino-alkylcyclohexane derivatives, pharmaceutical compositions containing them and use thereof
GEP20074075B (en) Indazolamides with analgesic activity
SV2006002238A (es) Inhibidores de la adenilato ciclasa soluble ref. p-sv-78. 959/gh
ITBO20020544A1 (it) Uso di farine vegetali come agenti biotossici ad azione ammendante.
TW200612994A (en) Scrubbing agent composition and skin cosmetic composition using the same
EP2258430A3 (de) 5-(Aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide und dessen medizinische Verwendung
GB0103240D0 (en) Organic compounds